# Efficacy, Safety and Pharmacokinetics of DTG with RIF

> **NCT03731559** · PHASE2 · RECRUITING · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 200 (estimated)

## Conditions studied

- HIV/TB Coinfection

## Interventions

- **DRUG:** DTG 50 mg OD with food
- **DRUG:** DTG 50 mg BID

## Key facts

- **NCT ID:** NCT03731559
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-25
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-10-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731559, "Efficacy, Safety and Pharmacokinetics of DTG with RIF". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03731559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*